Currently Viewing:
The Academy of Managed Care Pharmacy (AMCP) 2019
Trust Is the Key Ingredient in Medicaid Value-Based Contracts, Manufacturers and Payers Agree
March 26, 2019
Keeping an Eye on Increasing Competition in the Specialty Drug Pipeline
March 27, 2019
Currently Reading
Dr Sebastian Schneeweiss on How Rapid-Cycle Analytics Can Identify High-Risk, High-Cost Patients
March 27, 2019
The Balancing Act of Using Pharmacy Strategies to Fight the Opioid Epidemic
March 27, 2019
Current and Future Status of Drug Pricing Reform as the Blueprint Approaches the 1-Year Mark
March 27, 2019
Dr Steven Pearson: ICER Can Provide More Information When a Drug is Approved With Limited Data
March 28, 2019
Sophie Schmitz on the Importance of Considering Value of Gene Therapies, Not Just Cost
March 28, 2019
Managing Cholesterol With PCSK9 Inhibitors and Overcoming Operational Challenges in Practice
March 28, 2019
Dr James Chambers Discusses Variability in Specialty Drug Coverage and Its Impact
March 29, 2019
Dr Michael Steinman Discusses Effective Strategies for Improving Medication Management
March 29, 2019
Costs of Living With HIV Can Be Mitigated by Rapid Initiation of ART Post Diagnosis
March 29, 2019
Real-Time Prescription Benefit Checks Could Provide Accurate Cost Estimates at the Point of Prescribing
April 01, 2019
Dr Brian MacDonald Explains How Technology Can Improve Patient Management Strategies
April 10, 2019
Dr Crescent Moore on the Effect of Step Therapy in MA Plans, Other Formulary Regulations
April 13, 2019
Dr Michael Steinman on the Importance of Medication Management Strategies for Older Adults
April 15, 2019
Dr Sebastian Schneeweiss: How Payers Can Benefit From Rapid-Cycle Analytics of Real-World Evidence
April 19, 2019
Dr Crescent Moore on Implementing Care Coordination Programs in Medicare
April 25, 2019
Dr Sebastian Schneeweiss Discusses How Rapid-Cycle Analytics Can Evaluate Drug Safety, Efficacy
May 01, 2019
Dr Michael Steinman Details Opportunities for Improving Medication Management Strategies
May 05, 2019
Dr Crescent Moore Outlines CMS' Efforts to Address the Opioid Epidemic
May 13, 2019
Dr Sebastian Schneeweiss: In 5 Years, Rapid-Cycle Analytics Will Account for Majority of Analyses
May 15, 2019
Dr Jane Barlow on Innovations, Limitations Within Alternative Payment Models
January 14, 2020

Dr Sebastian Schneeweiss on How Rapid-Cycle Analytics Can Identify High-Risk, High-Cost Patients

Rapid-cycle anlytics of real-world evidence has an advantage over current strategies for analyzing real-world evidence because it is efficient, transparent, and scientifically validated, Sebastian Schneeweiss, MD, ScD, professor of medicine and epidemiology, Harvard Medical School and Brigham and Women's Hospital, and co-founder of Aetion.


Rapid-cycle anlytics of real-world evidence has an advantage over current strategies for analyzing real-world evidence because it is efficient, transparent, and scientifically validated, Sebastian Schneeweiss, MD, ScD, professor of medicine and epidemiology, Harvard Medical School and Brigham and Women's Hospital, and cofounder of Aetion.

Transcript

Rapid-cycle analytics of real-world evidence has been labeled a promising approach for identifying high-risk, high-cost patients. How does this approach improve upon how evidence is currently analyzed?

So, health plans need this type of evidence all the time, and they have hundreds of analysts going through the data, usually claims data and sometimes electronic health record data, in order to identify such patients and intervene on those patients. What is different between the traditional approach and rapid-cycle analytics is that in the traditional approach, you have line programming happening. People have statistical software packages and they write codes, and they write codes over and over again. That is not very transparent; you don’t know exactly what was done, you trust the analyst. It’s not very efficient, it’s not fast, it’s not replicatable, it’s not transparent, and these are all issues that translate into the usability of the findings. It’s not saying these findings are wrong, necessarily, they’re just less useful for the key stakeholders.

What rapid cycle analytics is doing is we take a platform and put the platform on top of the data, and then whatever question comes along, we can use this analytic platform in order to analyze these questions about who are the high-risk patients, what is the most effective treatment, what is the most safe treatment in these patients. We can do this much faster now because the software is already connected with the data. We can do this much more transparently, we can immediately produce reports on what kind of coding exactly was used, and things like that.

Decision makers really appreciate the fact that they get the findings fast, that they get the findings scientifically validated, and they get the findings transparently. That is key for decision making, we think.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up